From: Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Oral selexipag dose, µg bid
IV selexipag dose, µg bid
Number of patients at dose level, n (%)
200
225
0
400
450
1 (5.0)
600
675
2 (10.0)
800
900
1000
1125
3 (15.0)
1200
1350
1400
1575
1600
1800
9 (45.0)